IMPURITIES AVAILABLE FOR 'Sunvozertinib'

Omsynth Lifesciences Pvt. Ltd. is one of the leading manufacturer and exporter of Sunvozertinib. Sunvozertinib (also known as DZD9008) is an investigational, next-generation EGFR tyrosine kinase inhibitor developed for non–small cell lung cancer (NSCLC). It is designed to selectively target EGFR exon 20 insertion mutations, a subtype known to be resistant to earlier EGFR inhibitors. The drug shows potent activity against mutant EGFR while sparing wild-type EGFR, improving tolerability compared with less selective agents. Sunvozertinib is orally administered and exhibits favorable pharmacokinetic properties, including sustained target inhibition. Clinical studies have demonstrated meaningful antitumor responses in patients previously treated with chemotherapy or other targeted therapies. It has also shown activity against certain acquired resistance mutations. Common adverse events include diarrhea, rash, stomatitis, and paronychia. Sunvozertinib continues to be evaluated globally as a promising therapy for EGFR-mutated NSCLC. Buy high quality Sunvozertinib from Omsynth Lifesciences.